Top

Journal of Experimental & Clinical Cancer Research

Published in:

Open Access 01-12-2014 | Research

A novel miR-219-SMC4-JAK2/Stat3 regulatory pathway in human hepatocellular carcinoma

Authors: Bo Zhou, Hongxu Chen, Dong Wei, Yi Kuang, Xiaobiao Zhao, Guangyao Li, Jun Xie, Ping Chen

Published in: Journal of Experimental & Clinical Cancer Research | Issue 1/2014

Abstract

Background

To understand the involvement of structural maintenance of chromosome 4 (SMC4) in the development and progression of hepatocellular carcinoma (HCC).

Methods

Real-time quantitative PCR and Western Blotting were applied to measure the expression of SMC4 in HCC samples and cell lines. The tumor-promoting effect of SMC4 was determined by WST-1, soft agar colony formation, cell motility and invasion assays. The SMC4 target signal pathway was identified by luciferase reporter and real-time quantitative PCR assays.

Results

The upregulation of SMC4 was frequently detected in HCC samples and cell lines. Functional assays demonstrated that SMC4 could effectively promote tumor cell growth rate, colony formation in soft agar, wound-healing and invasion. Further studies showed that increased miR-219 levels caused a significant decrease in the SMC4 expression, and SMC4 inhibitor downregulated JAK2/Stat3 expression at both the mRNA and protein levels.

Conclusions

Our findings provide new insight into SMC4 function and the mechanisms of growth and invasion of HCC.

Available only for authorised users

Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM: Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010, 127: 2893-2917.CrossRefPubMed

Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D: Global cancer statistics. CA Cancer J Clin. 2011, 61: 69-90.PubMedCrossRef

Hernandez-Gea V, Toffanin S, Friedman SL, Llovet JM: Role of the microenvironment in the pathogenesis and treatment o hepatocellular carcinoma. Gastroenterology. 2013, 144: 512-527.PubMedCrossRef

Dibisceglie AM: Issues in screening and surveillance for hepatocellular carcinoma. Gastroenterology. 2004, 1275: 104-107.CrossRef

Fan MQ, Huang CB, Gu Y, Xiao Y, Sheng JX, Zhong L: Decrease expression of microRNA-20a promotes cancer cell proliferation and predicts poor survival of hepatocellular carcinoma. J Exp Clin Cancer Res. 2013, 32: 21-PubMedPubMedCentralCrossRef

Kuo YH, Lu SN, Chen CL, Cheng YF, Lin CY, Hung CH, Chen CH, Changchien CS, Hsu HC, Hu TH, Lee CM, Wang JH: Hepatocellular carcinoma surveillance and appropriate treatment options improve survival for patients with liver cirrhosis. Eur J Cancer. 2010, 46: 744-751.PubMedCrossRef

Toffanin S, Hoshida Y, Lachenmayer A, Villanueva A, Cabellos L, Minguez B, Savic R, Ward SC, Thung S, Chiang DY, Alsinet C, Tovar V, Roayaie S, Schwartz M, Bruix J, Waxman S, Friedman SL, Golub T, Mazzaferro V, Llovet JM: MicroRNA-based classification of hepatocellular carcinoma and oncogenic role of miR-517a. Gastroenterology. 2011, 140: 1618-1628.PubMedCrossRef

Villanueva A, Newell P, Chiang DY, Friedman SL, Llovet JM: Genomics and signaling pathways in hepatocellular carcinoma. Semin Liver Dis. 2007, 27: 55-76.PubMedCrossRef

Zucman-Rossi J, Laurent-Puig P: Genetic diversity of hepatocellular carcinomas and its potential impact on targeted therapies. Pharmacogenomics. 2007, 8: 997-1003.PubMedCrossRef

10.

Hoshida Y, Toffanin S, Lachenmayer A, Villanueva A, Minguez B, Llovet JM: Molecular classification and novel targets in hepatocellular carcinoma: recent advancements. Semin Liver Dis. 2010, 30: 35-51.PubMedPubMedCentralCrossRef

11.

Zeng C, Wang R, Li D, Lin XJ, Wei QK, Yuan Y, Wang Q, Chen W, Zhuang SM: A novel GSK-3 beta–C/EBP alpha–miR-122–insulin-like growth factor 1 receptor regulatory circuitry in human hepatocellular carcinoma. Hepatology. 2010, 52: 1702-1712.PubMedCrossRef

12.

Xiao Q, Qu K, Wang C, Kong Y, Liu C, Jiang D, Saiyin H, Jia F, Ni C, Chen T, Zhang Y, Zhang P, Qin W, Sun Q, Wang H, Yi Q, Liu J, Huang H, Yu L: HDGF-related protein-3 is required for anchorage-independent survival and chemoresistanc in hepatocellular carcinomas. Gut. 2013, 62: 440-451.PubMedCrossRef

13.

Xia L, Huang W, Tian D, Chen Z, Zhang L, Li Y, Hu H, Liu J, Chen Z, Tang G, Dou J, Sha S, Xu B, Liu C, Ma J, Zhang S, Li M, Fan D, Nie Y, Wu K: ACP5, a direct transcriptional target of FoxM1, promotes tumor metastasis and indicates poor prognosis in hepatocellular carcinoma. Oncogene. 2014, 33: 1395-406.PubMedCrossRef

14.

Kisseleva T, Bhattacharya S, Braunstein J, Schindler CW: Signaling through the JAK / STAT pathway, recent advances and future challenges. Gene. 2002, 285: 1-24.PubMedCrossRef

15.

Huang N, Lin J, Ruan J, Su N, Qing R, Liu F, He B, Lv C, Zheng D, Luo R: MiR-219-5p inhibits hepatocellular carcinoma cell proliferation by targeting glypican-3. FEBS Lett. 2012, 586: 884-891.PubMedCrossRef

16.

Huynh H: Molecularly targeted therapy in hepatocellular carcinoma. Biochem Pharmacol. 2010, 80: 550-560.PubMedCrossRef

17.

Zhou B, Yuan T, Liu M, Liu H, Xie J, Shen Y, Chen P: Overexpression of the structural maintenance of chromosome 4 protein is associated with tumor de- differentiation, advanced stage and vascular invasion of primary liver cancer. Oncol Rep. 2013, 28: 1263-1268.CrossRef

18.

Kong KL, Kwong DL, Chan TH, Law SY, Chen L, Li Y, Qin YR, Guan XY: MicroRNA −375 inhibits tumour growth and metastas in oesophageal squamous cell carcinoma through epressing insulin-like growth factor 1 receptor. Gut. 2013, 61: 33-42.CrossRef

19.

Kong KL, Kwong DL, Fu L, Chan TH, Chen L, Liu H, Li Y, Zhu YH, Bi J, Qin YR, Law SY, Guan XY: Characterization of a candidate tumor suppresso gene uroplakin 1A in esophageal squamous cell carcinoma. Cancer Res. 2010, 70: 8832-8841.PubMedCrossRef

20.

McDowall MD, Scott MS, Barton GJ: PIPs: Human protein-protein interactions prediction database. Nucleic Acids Res. 2009, 37: 651-656.CrossRef

21.

Yellaboina S, Tasneem A, Zaykin DV, Raghavachari B, Jothi R: DOMINE: A comprehensive collection of known and predicted domain-domain interactions. Nucleic Acids Res. 2011, 39: 730-735.CrossRef

22.

Losada A, Hirano T: Dynamic molecular linkers of the genome: the first decade of SMC proteins. Genes Dev. 2005, 19: 1269-1287.PubMedCrossRef

23.

Griese JJ, Hopfner KP: Structure and DNA-binding activity of the Pyrococcus furiosus SMC protein hinge domain. Proteins. 2011, 79: 558-568.PubMedCrossRef

24.

Hirano T: Condensins: Organizing and segregating the genome. Curr Biol. 2005, 15: 265-275.CrossRef

25.

Freeman L, Aragon-Alcaide L, Strunnikov A: The condensing complex governs chromosome condensation and mitotic transmission of rDNA. J Cell Biol. 2000, 149: 811-824.PubMedPubMedCentralCrossRef

26.

Yu L, Peña Castillo L, Mnaimneh S, Hughes TR, Brown GW: A survey of essential gene function in the yeast cell division cycle. Mol Biol Cell. 2006, 17: 4736-4747.PubMedPubMedCentralCrossRef

27.

Chang H, Jeung HC, Jung JJ, Kim TS, Rha SY, Chung HC: Identification of genes associated with chemosensitivity to SAHA/taxane combination treatment in taxane- resistant breast cancer cells. Breast Cancer Res Treat. 2011, 125: 55-63.PubMedCrossRef

28.

Lei H, Zou D, Li Z, Luo M, Dong L, Wang B, Yin H, Ma Y, Liu C, Wang F, Zhang J, Yu J, Li Y: MicroRNA-219-2-3p functions as a tumor suppressor in gastric cancer and is regulated by DNA methylation. PLoS One. 2013, 8: e60369-PubMedPubMedCentralCrossRef

29.

Wong TS, Liu XB, Wong BY, Ng RW, Yuen AP, Wei WI: Mature miR-184 as potential oncogenic microRNA of squamous cell carcinoma of tongue. Clin Cancer Res. 2008, 14: 2588-2592.PubMedCrossRef

30.

Dugas JC, Cuellar TL, Scholze A, Ason B, Ibrahim A, Emery B, Zamanian JL, Foo LC, McManus MT, Barres BA: Dicer1 andmiR-219 Are requiredfor normal oligodendrocyte differentiation andmyelination. Neuron. 2010, 65: 597-611.PubMedPubMedCentralCrossRef

31.

Ho M, Kim H: Glypican-3: a new target for cancer immunotherapy. Eur J Cancer. 2011, 47: 333-338.PubMedCrossRef

32.

Yu H, Pardoll D, Jove R: STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer. 2009, 9: 798-809.PubMedPubMedCentralCrossRef

33.

Yu H, Jove R: The STATs of cancer-new molecular targets come of age. Nat Rev Cancer. 2004, 4: 97-105.PubMedCrossRef

34.

Niu G, Wright KL, Huang M, Song L, Haura E, Turkson J, Zhang S, Wang T, Sinibaldi D, Coppola D, Niu G, Wright KL, Huang M, Song L, Haura E, Turkson J, Zhang S, Wang T, Sinibaldi D, Coppola D, Heller R, Ellis LM, Karras J, Bromberg J, Pardoll D, Jove R, Yu H: Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis. Oncogene. 2002, 21: 2000-2008.PubMedCrossRef

35.

Real PJ, Sierra A, De Juan A, Segovia JC, Lopez-Vega JM, Fernandez-Luna JL: Resistance to chemotherapy via Stat3-dependent overexpression of Bcl-2 in metastatic breast cancer cells. Oncogene. 2002, 21: 7611-7618.PubMedCrossRef

36.

Wang T, Niu G, Kortylewski M, Burdelya L, Shain K, Zhang S, Bhattacharya R, Gabrilovich D, Heller R, Coppola D, Dalton W, Jove R, Pardoll D, Yu H: Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells. Nat Med. 2004, 10: 48-54.PubMedCrossRef

37.

Liu Y, Liu A, Li H, Li C, Lin J: Celecoxib inhibits interleukin-6/interleukin-6 receptor- induced JAK2/STAT3 phosphorylation in human hepatocellular carcinoma cells. Cancer Prev Res. 2011, 4: 1296-1305.CrossRef

38.

Morita Y, Naka T, Kawazoe Y, Fujimoto M, Narazaki M, Nakagawa R, Fukuyama H, Nagata S, Kishimoto T: Signals transducers and activators of transcription (STAT) -induced STAT inhibitor-1 (SSI-1)/suppressor of cytokine signaling-1 (SOCS-1) suppresses tumor necrosis factor alpha-induced cell death in fibroblasts. Proc Natl Acad. Sci USA. 2000, 97: 5405-5410.PubMedPubMedCentralCrossRef

39.

Gamero AM, Young HA, Wiltrout RH: Inactivation of Stat3 in tumor cells: releasing a brake on immune responses against cancer?. Cancer Cell. 2004, 5: 111-112.PubMedCrossRef

40.

Subramaniam A, Anmugam MK, Perumal E, Li F, Nachiyappan A, Dai X, Swamy SN, Ahn KS, Kumar AP, Tan BK, Hui KM, Sethi G: Potential role of signal transducer and activator of transcription (STAT)3 signaling pathway in inflammation, survival, proliferation and invasion of hepatocellular carcinoma. Biochim Biophys Acta. 1835, 2013: 46-60.

41.

Chen X, Ying Z, Lin X, Lin H, Wu J, Li M, Song L: Acylglycerol kinase augments JAK2/STAT3 signaling in esophageal squamous cells. J Clin Invest. 2013, 123: 2576-2589.PubMedPubMedCentralCrossRef

42.

Wen Z, Darnell JE: Mapping of Stat3 serine phosphorylation to a single residue (727) and evidence that serine phosphorylation has no influence on DNA binding of Stat1 and Stat3. Nucleic Acids Res. 1997, 25: 2062-2067.PubMedPubMedCentralCrossRef

Title: A novel miR-219-SMC4-JAK2/Stat3 regulatory pathway in human hepatocellular carcinoma
Authors: Bo Zhou
Hongxu Chen
Dong Wei
Yi Kuang
Xiaobiao Zhao
Guangyao Li
Jun Xie
Ping Chen
Publication date: 01-12-2014
Publisher: BioMed Central
Published in: Journal of Experimental & Clinical Cancer Research / Issue 1/2014
Electronic ISSN: 1756-9966
DOI: https://doi.org/10.1186/1756-9966-33-55

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2014

Pegylated arginine deiminase synergistically increases the cytotoxicity of gemcitabine in human pancreatic cancer

Overexpression of brachyury contributes to tumor metastasis by inducing epithelial-mesenchymal transition in hepatocellular carcinoma

Bromelain and N-acetylcysteine inhibit proliferation and survival of gastrointestinal cancer cells in vitro: significance of combination therapy

Transactivation of epidermal growth factor receptor through platelet-activating factor/receptor in ovarian cancer cells

Journal of Experimental & Clinical Cancer Research revieweracknowledgement 2013

Detection of ALK protein expression in lung squamous cell carcinomas by immunohistochemistry

Keynote webinar | Spotlight on antibody–drug conjugates in cancer